IP Library › Granted Patent US 11,826,405
Granted Patent B2
US 11,826,405 · App. 17/006,685 · Granted Nov 28, 2023

Neurotoxin compositions for use in treating headache

Inventors: Gregory F. Brooks (Irvine, CA); Andrew M. Blumenfeld (Del Mar, CA)
Assignee: Aeon Biopharma, Inc.
A61K38/4893A61P25/16C12Y304/24069
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,826,405
App. No.
17/006,685
Granted
Nov 28, 2023
Kind
B2
Abstract

Disclosed herein are compositions and methods for use in treating headache.

Claims (59)

1. A method for treating a migraine headache comprising:

a) administering about 10 units of a botulinum neurotoxin into the upper frontalis at the hairline, and further administering the neurotoxin to at least five of the muscle regions selected from the corrugator, masseter, nasalis, oculi, occipitalis, temporalis, and trapezius muscle regions, and wherein the cervical paraspinal muscle and procerus muscles are not administered-to;

b) thereby treating the migraine headache.

2. The method of claim 1 , wherein a second botulinum neurotoxin is administered bilaterally into the sphenopalatine ganglion (SPG).

3. The method of claim 1 , wherein said botulinum neurotoxin is further administered to between five six and seven eight of the muscle regions selected from the corrugator, masseter, nasalis, occipitalis, temporalis, trapezius and oculi muscle regions.

4. The method of claim 1 , wherein said botulinum neurotoxin is further administered to the corrugator, occipitalis, temporalis, and trapezius muscle regions.

5. The method of claim 1 , wherein said botulinum neurotoxin is further administered to the corrugator, occipitalis, temporalis, oculi and trapezius muscle regions.

6. The method of claim 1 , wherein said botulinum neurotoxin is further administered to the corrugator, occipitalis, temporalis, oculi, masseter and trapezius muscle regions.

7. The method of claim 1 , wherein said botulinum neurotoxin is further administered to the corrugator, occipitalis, temporalis, oculi, nasalis, and trapezius muscle regions.

8. The method of claim 1 , wherein said botulinum neurotoxin is further administered to the corrugator, occipitalis, temporalis, oculi, nasalis, masseter and trapezius muscle regions.

9. The method of claim 1 , wherein said migraine headache is an episodic migraine or a chronic migraine.

10. The method of claim 9 , wherein said migraine headache is an episodic migraine.

11. The method of claim 9 , wherein said migraine headache is a chronic migraine.

12. The method of claim 1 , wherein said botulinum neurotoxin comprises botulinum type A.

13. The method of claim 1 , wherein said botulinum neurotoxin comprises botulinum type B, C, D, E, or F.

14. The method of claim 1 , wherein the total dose of said botulinum neurotoxin is about 145-200 Units.

15. The method of claim 1 , wherein the total dose of said botulinum neurotoxin is about 195 Units.

16. The method of claim 1 , wherein the total dose of said botulinum neurotoxin is about 150 Units.

17. The method of claim 1 , wherein said administration to said corrugator comprises administration of said botulinum neurotoxin in an amount of about 10 Units.

18. The method of claim 1 , wherein said administration to said oculi comprises administration of said botulinum neurotoxin in an amount of about 10 Units.

19. The method of claim 1 , wherein said administration to said temporalis comprises administration of said botulinum neurotoxin in an amount of about 30 Units anterior to the tragus.

20. The method of claim 1 , wherein said administration to said temporalis comprises administration of said botulinum neurotoxin in an amount of about 60 Units anterior to the tragus.

21. The method of claim 1 , wherein said administration to said nasalis comprises administration of said botulinum neurotoxin in an amount of about 5 Units.

22. The method of claim 1 , wherein said administration to said masseter comprises administration of said botulinum neurotoxin in an amount of about 10 Units.

23. The method of claim 1 , wherein said administration to said occipitalis comprises administration of said botulinum neurotoxin in an amount of about 60 Units.

24. The method of claim 1 , wherein said administration to said trapezius comprises administration of said botulinum neurotoxin in an amount of about 30 Units.

25. The method of claim 24 , wherein said administration to said trapezius comprises superficial administration of said botulinum neurotoxin in an amount of about 10 Units to the superior trapezius.

26. The method of claim 1 , wherein said nasalis is not administered-to.

27. The method of claim 1 , wherein said masseter is not administered-to.

28. A fixed-site, fixed-dose method for treating migraine with 22 individual botulinum administrations comprising:

administering a botulinum toxin to the superior trapezius at a dosage of about 5 units per site at one site on each side of the head and about 10 units per site to the inferior trapezius at one site on each side of the head; and

administering a botulinum toxin to the occipitalis at a dosage of about 10 units per site at three sites on each side of the head; and

administering a botulinum toxin to the temporalis at a dosage of about 5 units per site at three sites on each side of the head; and

administering a botulinum toxin to the oculi at a dosage of about 5 units to one site on each side of the head; and

administering a botulinum toxin to the corrugator at a dosage of about 5 units to one site on each side of the head; and

administering a botulinum toxin to the upper frontalis at the hairline at a dosage of about 5 units to one site on each side of the head;

wherein the botulinum toxin is not administered to the cervical paraspinal or procerus muscles;

thereby treating the migraine with a total of about 150 Units.

29. A fixed-site, fixed-dose method for treating migraine with 26 individual botulinum administrations comprising:

administering a botulinum toxin to the superior trapezius at a dosage of about 5 units per site at one site on each side of the head and about 10 units per site to the inferior trapezius at one site on each side of the head; and

administering a botulinum toxin to the occipitalis at a dosage of about 10 units per site at three sites on each side of the head; and

administering a botulinum toxin to the temporalis at a dosage of about 10 units per site at three sites on each side of the head; and

administering a botulinum toxin to the oculi at a dosage of about 5 units to one site on each side of the head; and

administering a botulinum toxin to the corrugator at a dosage of about 5 units to one site on each side of the head; and

administering a botulinum toxin to the upper frontalis at the hairline at a dosage of about 5 units to one site on each side of the head; and

administering a botulinum toxin to the nasalis at a dosage of about 2.5 units to one site on each side of the head; and

administering a botulinum toxin to the masseter at a dosage of about 5 units to one site on each side of the head;

wherein the botulinum toxin is not administered to the cervical paraspinal or procerus muscles;

thereby treating the migraine with a total of about 195 Units.

30. A fixed site method for treating migraine headache with 24 individual botulinum administrations comprising:

administering a botulinum toxin to the superior trapezius at a dosage of about 3-10 units per site at one site on each side of the head and 5-15 units per site to the inferior trapezius at one site on each side of the head; and

administering a botulinum toxin to the occipitalis at a dosage of about 7-15 units per site at three sites on each side of the head; and

administering a botulinum toxin to the temporalis at a dosage of about 3-15 units per site at three sites on each side of the head; and

administering a botulinum toxin to the oculi at a dosage of about 3-10 units to one site on each side of the head; and

administering a botulinum toxin to the corrugator at a dosage of about 3-10 units to one site on each side of the head; and

administering a botulinum toxin to the upper frontalis at the hairline at a dosage of about 3-10 units to one site on each side of the head; and

administering a botulinum toxin to at least one of the nasalis and masseter, wherein said nasalis administration is at a dosage of about 1-5 units to one site on each side of the head; and said masseter administration is at a dosage of about 3-10 units to one site on each side of the head;

wherein the botulinum toxin is not administered to the cervical paraspinal or procerus muscles;

thereby treating the migraine headache.

Assignments (7)
PATENT SECURITY AGREEMENT Recorded Jan 22, 2026
From: AEON BIOPHARMA SUB, INC.
To: DAEWOONG PHARMACEUTICAL CO., LTD.
Reel/Frame 074476/0932 →
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL Recorded Jan 22, 2026
From: DAEWOONG PHARMACEUTICAL CO., LTD.
To: AEON BIOPHARMA, INC.; AEON BIOPHARMA SUB, INC.
Reel/Frame 074476/0802 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2024
From: AEON BIOPHARMA, INC.
To: AEON BIOPHARMA SUB, INC.
Reel/Frame 066876/0628 →
SECURITY INTEREST Recorded Mar 20, 2024
From: AEON BIOPHARMA, INC.; AEON BIOPHARMA SUB, INC.
To: DAEWOONG PHARMACEUTICAL CO., LTD.
Reel/Frame 066847/0164 →
SECURITY INTEREST Recorded Mar 19, 2024
From: AEON BIOPHARMA, INC.
To: DAEWOONG PHARMACEUTICAL CO., LTD.
Reel/Frame 066830/0138 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2021
From: BLUMENFELD, ANDREW M.
To: AEON BIOPHARMA, INC.
Reel/Frame 056505/0832 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2021
From: BROOKS, GREGORY F.
To: AEON BIOPHARMA, INC.
Reel/Frame 056505/0871 →
Continuity (5)
Provisional Application 63029304 · May 22, 2020
Provisional Application 63011168 · Apr 16, 2020
Provisional Application 62950775 · Dec 19, 2019
Provisional Application 62894540 · Aug 30, 2019
Related Publication 20210060144A1 · Mar 4, 2021